Orencia (abatacept) is a prescription biologic medication used primarily to treat autoimmune forms of arthritis. It has four FDA-approved uses: rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in children ages 2 and older, psoriatic arthritis in adults, and prevention of acute graft-versus-host disease in patients undergoing stem cell transplants.
How Orencia Works
Orencia belongs to a class of drugs called selective costimulation modulators. Your immune system relies on T cells to coordinate attacks against threats, but in autoimmune diseases, those T cells mistakenly target your own tissues. To fully activate, T cells need two signals. Orencia blocks the second signal by binding to specific proteins on immune cells (CD80 and CD86), preventing them from connecting with T cells. Without that connection, the T cells don’t fully switch on, which dials down the overactive immune response driving joint inflammation and damage.
This mechanism is different from TNF inhibitors, another common class of biologic used for arthritis. Rather than neutralizing an inflammatory molecule after it’s been released, Orencia works upstream by preventing the immune cells from ramping up in the first place.
Rheumatoid Arthritis
The most common reason Orencia is prescribed is moderately to severely active rheumatoid arthritis in adults. According to the American College of Rheumatology, Orencia is often started after other disease-modifying drugs like methotrexate haven’t provided enough relief, though it can also be used as a first-line therapy. It reduces joint pain, swelling, and stiffness, and slows the structural joint damage that RA causes over time.
Most people with RA take Orencia as a weekly self-injection at home. It’s also available as an intravenous infusion given at a clinic, typically every four weeks after an initial loading period. The subcutaneous version comes in prefilled syringes (in 50 mg, 87.5 mg, and 125 mg doses) and a spring-loaded autoinjector called ClickJect. The autoinjector is a single-button device that makes self-injection simpler for people uncomfortable with handling a syringe manually.
Juvenile Idiopathic Arthritis
Orencia is approved for children ages 2 and older with polyarticular juvenile idiopathic arthritis, a condition where multiple joints become inflamed. “Polyarticular” means five or more joints are affected, and it can significantly impact a child’s growth, mobility, and daily activities if not controlled.
How the medication is given depends on the child’s age. Children 2 and older can receive subcutaneous injections, with the dose adjusted by weight using smaller prefilled syringes. Intravenous infusions are reserved for children 6 and older, administered in a clinical setting. The goal is the same as in adult RA: reduce active inflammation and prevent long-term joint damage during critical years of development.
Psoriatic Arthritis
Orencia is also approved for active psoriatic arthritis in adults. Psoriatic arthritis combines joint inflammation with the skin plaques of psoriasis, and treatments don’t always address both equally well. Clinical data shows that Orencia reduces joint disease activity and appears to protect bone at the joint level. A prospective imaging study found that patients taking weekly 125 mg injections for 24 weeks developed no new bone erosions or structural damage at the points where tendons attach to bone, suggesting a protective effect on the skeleton beyond just symptom relief.
Orencia is generally considered for psoriatic arthritis when the joint component is the primary concern. Other biologics may be preferred when skin symptoms are more prominent.
Graft-Versus-Host Disease Prevention
Orencia’s newest approved use is preventing acute graft-versus-host disease (aGVHD) in people receiving stem cell transplants from unrelated donors. In a stem cell transplant, the donor’s immune cells can attack the recipient’s body, causing potentially life-threatening damage to the skin, liver, and gut. Orencia is given alongside two other immune-suppressing medications to reduce this risk.
The dosing schedule for this use is precise and time-limited. Patients 6 and older receive an IV infusion the day before transplant, then again on days 5, 14, and 28 after transplant. Younger children (ages 2 to 5) receive a slightly higher weight-based dose on day one, then a lower dose on the same post-transplant schedule. This is not a long-term therapy; it’s a short course designed to calm the transplanted immune system during the critical first month.
Common Side Effects
Because Orencia tamps down part of the immune system, the most notable risk is increased susceptibility to infections. Upper respiratory infections, sinus congestion, sore throat, and urinary tract infections are among the most commonly reported side effects. Headache, nausea, back pain, and general fatigue also appear frequently in clinical trial data.
Infusion-related reactions can occur with the IV form, including dizziness, headache, or changes in blood pressure during or shortly after the infusion. These tend to be mild and become less common over time. Injection site reactions with the subcutaneous form are generally minor, limited to redness or mild swelling.
Important Safety Considerations
Orencia should not be taken alongside TNF inhibitors (such as adalimumab, etanercept, or infliximab) or with anakinra, another type of immune-modulating drug. Clinical trials tested this combination and found no added benefit for joint symptoms, but infection rates climbed sharply. Patients on both Orencia and a TNF inhibitor experienced infections at a rate of 63%, compared to 43% for those on a TNF inhibitor alone. Serious infections were more than five times higher in the combination group (4.4% versus 0.8%).
Before starting Orencia, screening for tuberculosis and hepatitis B is standard practice because suppressing T-cell activity can allow dormant infections to reactivate. Live vaccines should also be avoided while on the medication, since the dampened immune response may not be able to handle even a weakened virus safely.
How Orencia Fits Into Treatment
For rheumatoid arthritis, Orencia occupies a similar position in the treatment hierarchy as TNF inhibitors and other biologics. Some rheumatologists reach for it first in patients who have risk factors that make TNF inhibitors less ideal, such as a history of certain infections or prior cancers. Others reserve it for patients who haven’t responded well to a TNF inhibitor, since its distinct mechanism means it can work even when TNF-targeting drugs have failed. It can be used with or without methotrexate, though combining the two is common and often more effective than either alone.
For psoriatic arthritis, Orencia tends to be positioned as an option when joint disease is the dominant problem. For graft-versus-host disease prevention, it fills a more specialized role as part of a multi-drug regimen during stem cell transplants from unrelated donors.